360° SearchNetwork Hot Spots Trends Time Series

Erythropoietin EPO

Type: Keyphrase

Name: Erythropoietin EPO

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Studies from Ain Shams University Further Understanding of Kidney Disease

(NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- Current study results on Kidney Disease have been published. According to news reporting from Cairo, Egypt, by NewsRx journalists, research stated, "The significance of glycated albumin ... [Published NewsRX - May 17 2013]

Entities: Kidney Disease, Glycated Hemoglobin, Diabetes

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Global Biosimilar Market Report 2013

Visiongain published a new report on the global biosimilar market in 2013 and says the market size will reach $2.45 B, or approximately 20% higher than last year. Biosimilars now account for about 2% of the biologics market. PharmTech Talk»Global Biosimilars ... [Published The Big Red Biotech Blog - May 16 2013]

Entities: Market, James Evans, Visiongain

First reported May 16 2013 - Updated May 16 2013 - 1 reports

Former cross-country skiers charged for false statements in court

2001 doping scandal continues to haunt Finnish cross-country skiing.FORMER CROSS-COUNTRY skiers Harri Kirvesniemi, Janne Immonen and Jari Isometsä will face charges of false statements in court in a trial scheduled to begin at the District Court of Helsinki ... [Published Helsinki Times - May 16 2013]

Entities: Jari Isometsä, Cross-Country Skiing, Doping, Jari Räsänen, Janne Immonen

First reported May 15 2013 - Updated May 16 2013 - 1 reports

Big Pharma ran secret trials in E. Germany

Western pharmaceutical companies paid the former East German regime millions to conduct secret and often unethical drug trials involving tens of thousands of patients, a German documentary has revealed.Hundreds of clinical trials were set up in more than ... [Published Australian Doctor - May 15 2013]

Entities: Big Pharma, Germany, Clinical trials

First reported May 15 2013 - Updated May 15 2013 - 1 reports

Acceleron Reports ACE-536 Preclinical Data Secures Best Abstract at 12th International Symposium on Myelodysplastic Syndromes

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan hematologic diseases, announced that preclinical research conducted by Acceleron scientists on the ACE-536 program received the Tito Bastianello ... [Published Individual.com - May 15 2013]

Entities: Red Blood Cell, anemia, Erythropoietin EPO, Myelodysplastic Syndromes

First reported May 13 2013 - Updated May 14 2013 - 1 reports

Agilent Technologies Inc

Agilent Technologies Introduces AdvanceBio Peptide Mapping Columns

Agilent Technologies Inc. today introduced the latest updates to its AdvanceBio family of columns. The new AdvanceBio Peptide Mapping BioHPLC and ZORBAX RRHD 300-HILIC columns are designed to deliver exceptional performance for the separation, characterization ... [Published Select Science - May 13 2013]

Entities: Peptide, Agilent Technologies Inc, Erythropoietin EPO, glycopeptide

First reported May 13 2013 - Updated May 14 2013 - 1 reports

Reports: 1997 Gent-Wevelgem winner Gaumont passes away in France

Ex-professional never recovered from cardiac arrestThree weeks after he suffered a heart attack at his home on April 23rd, French media is reporting that former pro Philippe Gaumont has passed away at 40 years of age.The 1997 Gent-Wevelgem winner was ... [Published Velonation - May 13 2013]

Entities: Philippe Gaumont, Gent-Wevelgem, Cofidis S A, Doping

First reported May 06 2013 - Updated May 06 2013 - 4 reports

Single, High-dose Erythropoietin Given 2 Days Pre-op Reduces Need for Transfused Blood

– Anemia increases operative mortality and morbidity in non-cardiac and cardiac surgical procedures. Anemic surgical patients may require more blood transfusions, raising the risk of transfusion-related complications and increasing costs. For those reasons, ... [Published ScienceNewsline - May 06 2013]

Entities: Erythropoietin EPO, anemia, Recombinant, Blood Transfusion, Morbidity

First reported May 05 2013 - Updated May 05 2013 - 2 reports

Cyclist White admits to doping from 1998

Australian Matt White has revealed he took performance-enhancing drugs for the majority of his professional cycling career, saying he became desensitised to the idea of injecting himself after initially feeling rattled.White, who last week announced he'd ... [Published BigPond News - May 05 2013]

Entities: Doping, Australian Sports Anti-Doping Authority, Performance Enhancing Drugs

First reported May 02 2013 - Updated May 02 2013 - 2 reports

EPO Pills: A Challenge For Amgen And Johnson & Johnson

Home » Blogs » For the past two and a half decades Amgen (AMGN) and Johnson & Johnson (JNJ) had the US Epogen market divided up among themselves: Amgen marketing the recombinant human erythropoietin primarily to dialysis patients and Johnson & Johnson ... [Published BioPortfolio - May 02 2013]

Entities: Erythropoietin EPO, Amgen Inc, Johnson & Johnson

First reported May 01 2013 - Updated May 01 2013 - 2 reports

Hospira Marks Five Years of Biosimilars Success at 2013 BIO . . .

Hospira Marks Five Years of Biosimilars Success at 2013 BIO International ConventionHospira, Inc.NewsRx.comBy a News Reporter-Staff News Editor at Investment Weekly News -- Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and ... [Published Equities.com - May 01 2013]

Entities: Hospira Inc, Erythropoietin EPO, Patient, United States

First reported Apr 19 2013 - Updated Apr 19 2013 - 4 reports

Astellas Pharma Inc., GlaxoSmithKline Vie to Make "High Altitude" Anemia Pill

Japan's Astellas Pharma and Britain's GlaxoSmithKline are competing to develop a new kind of medicine that boosts production of red blood cells by making the body think it is at high altitude. Their experimental drugs - both given as pills - could create ... [Published BioSpace - Apr 19 2013]

Entities: Astellas Pharma Inc, anemia, GlaxoSmithKline plc, Altitude, Erythropoietin EPO

Quotes

According to the news reporters, the research concluded: "It is suggested that GA provides a significantly better measure to estimate glycemic control in HD patients with diabetes and that the assessment of glycemic control by HbA1c in these patients might lead to likely underestimation as a result of the increasing proportion of young erythrocyte by the use of erythropoietin."

Studies from Ain Shams University Further Understanding of Kidney Disease [Published NewsRX - May 17 2013]

...Biosimilar erythropoietin and filagrastim are also expected to have increasing impact. Said pharma industry analyst, James Evans, "Biologics are going to become so..."

Global Biosimilar Market Report 2013 [Published The Big Red Biotech Blog - May 16 2013]

"The team made a commitment to the MPCC to comply with its rules," Lavenu said. "This may serve as an electric shock for everybody, to fully understand what the stakes are."

AG2R La Mondiale to sit out Dauphiné if Sylvain Georges’ B-sample is positive [Published Velonation - May 16 2013]

...rationale for the encouraging effects shown in this preclinical MDS model", said Ravi Kumar, Ph D , Chief Scientific Officer of Acceleron. "The potential of ACE-536 to correct the anemia by targeting ineffective erythropoiesis is very exciting and applicable to other diseases, such as beta thalassemia, in which ineffective erythropoiesis leads to serious and chronic anemia and where there are few treatment options."

Acceleron Reports ACE-536 Preclinical Data Secures Best Abstract at 12th International Symposium ... [Published Individual.com - May 15 2013]

More Content

sort by: Date \| Relevance
Extractables and Leachables: Best Practices to ... [Published BioPharm International - 22 hours ago]
Studies from Ain Shams University Further Under... [Published NewsRX - May 17 2013]
Global Biosimilar Market Report 2013 [Published The Big Red Biotech Blog - May 16 2013]
AG2R La Mondiale to sit out Dauphiné if Sylvain... [Published Velonation - May 16 2013]
Former cross-country skiers charged for false s... [Published Helsinki Times - May 16 2013]
Should Human Genes Be Patentable? [Published Atlantic Monthly - May 16 2013]
Should Human Genes Be Patentable? [Published The Daily Dish \| By Andrew Sullivan - May 16 2013]
Acceleron Reports ACE-536 Preclinical Data Secu... [Published Individual.com - May 15 2013]
Big Pharma ran secret trials in E. Germany [Published Australian Doctor - May 15 2013]
Global biosimilar market will grow to $2.44bn t... [Published Terrapinn - May 14 2013]
Agilent Technologies Introduces AdvanceBio Pept... [Published Equities.com - May 14 2013]
A sweet deal [Published Drug Discovery News - May 13 2013]
Reports: 1997 Gent-Wevelgem winner Gaumont pass... [Published Velonation - May 13 2013]
Agilent Technologies Introduces AdvanceBio Pept... [Published Select Science - May 13 2013]
Part 2: Will Array BioPharma Become A Late-Stag... [Published Seeking Alpha - May 12 2013]
Proactive Investors Mid & Sml Cap Weekly Roundu... [Published Proactiveinvestors United Kingdom RSS feed - May 11 2013]
Amgen Tour of California -Kick-off press confer... [Published Examiner.com - May 11 2013]
Acceleron’s ACE-536 Preclinical Data Presentati... [Published Business Wire - May 10 2013]
Intas launches "Mabtas", its biosimilar version... [Published IndiaPRwire - May 10 2013]
Rockwell Medical Set to Disrupt Dialysis Treatm... [Published Xconomy - May 09 2013]
Oncobiologics, Zhejiang Huahai Form Global Alli... [Published Pharmacy Choice - May 09 2013]
Xenetic Biosciences starts Phase III trial for ... [Published Proactiveinvestors United Kingdom RSS feed - May 09 2013]
Xenetic's Phase III study of ErepoXen doses fir... [Published Stock Market Wire - May 09 2013]
"Compositions of Botanical Extracts for Cancer ... [Published Pharmacy Choice - May 09 2013]
Sex differences in blood genotoxic and cytotoxi... [Published Bionity.com - May 09 2013]
U.S. to contribute to 'rapid' biosimilar market... [Published Drug Store News - May 07 2013]
Single, High-Dose Erythropoietin Given 2 Days P... [Published BioSpace - May 07 2013]
More Scottish children are losing parents to dr... [Published Individual.com - May 07 2013]
The pitfalls of adolescent ardor [Published Sonoma Index-Tribune - May 07 2013]
Prognosis of Dialysed Patients after Kidney Tra... [Published Sexual Development - May 07 2013]

Blogs

sort by: Date \| Relevance
Global Biosimilar Market Report 2013 [Published The Big Red Biotech Blog - May 16 2013] Visiongain published a new report on the global biosimilar market in 2013 and says the market size will reach $2.45 B, or approximately 20% higher than last year. Biosimilars now account for about 2% of the biologics market. PharmTech Talk»Global Biosimilars ...
Should Human Genes Be Patentable? [Published The Daily Dish \| By Andrew Sullivan - May 16 2013] Florence Williams asks why a company should be allowed to patent the genes that prompted Jolie’s double mastectomy: Although they reside in our bodies, the BRCA genes are effectively owned by a bio-tech giant, Myriad Genetics, which patented the ...
U.S. government sues Lance Armstrong under Fals... [Published Financial Post \| Business » Legal Post - Apr 24 2013] Lance Armstrong, the former champion cyclist, defrauded the U.S. by using banned substances, the government said in a complaint filed under the False Claims Act that joins a lawsuit brought by his ex-teammate Floyd Landis. The Justice Department, in ...
MKSAP: 65-year-old man with daytime somnolence [Published KevinMD.com - Mar 16 2013] Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians . A 65-year-old man is evaluated for a 2-year history of daytime somnolence, snoring, and apneic episodes during the night as witnessed by ...
The quest for generic biotechnology pharmaceuti... [Published Biotech Blog - Feb 27 2013] Copyright © thinkBiotech This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology The quest for generic biotechnology pharmaceuticals in the USA Go to paper ABSTRACT: As patent protection expires on ...

Press Releases

sort by: Date \| Relevance
Acceleron’s ACE-536 Preclinical Data Presentati... [Published Business Wire - May 10 2013]
New Neuro NICU at Packard Children’s Specialize... [Published Business Wire - Apr 30 2013]
Research and Markets: Competitor Analysis: Eryt... [Published Business Wire - Apr 18 2013]
Research and Markets: Competitor Analysis: Eryt... [Published Business Wire Health News - Apr 18 2013]
Winning At Any Cost!?! Blood Transfusions. EPO.... [Published PR Newswire: Entertainment & Media - Apr 01 2013]